Literature DB >> 2219737

Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins.

H A Overton1, D J McMillan, S J Gridley, J Brenner, S Redshaw, J S Mills.   

Abstract

The ability of two novel synthetic compounds to inhibit the HIV protease-mediated processing of HIV-1 precursor polyproteins was investigated in an in vitro gag-protease mixed lysate assay system and in an assay using recombinant baculoviruses engineered to express the HIV-1 gag and pol genes in cultured insect cells. With the in vitro mixed lysate assay we have shown that both compounds at 1 microM can completely inhibit the HIV-1 and HIV-2 protease-mediated release of p24 from the HIV-1 gag precursor at pH 5.5 and pH 7.0. In the intracellular baculovirus system these compounds were shown to inhibit the protease-mediated maturation of gag and also the excision of the protease moiety from its precursor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219737     DOI: 10.1016/0042-6822(90)90326-m

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.

Authors:  R R Speck; C Flexner; C J Tian; X F Yu
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation.

Authors:  L M Babé; C S Craik
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 3.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

5.  Assembly-defective point mutants of the human immunodeficiency virus type 1 Gag precursor phenotypically expressed in recombinant baculovirus-infected cells.

Authors:  S S Hong; P Boulanger
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.

Authors:  M A el-Farrash; M J Kuroda; T Kitazaki; T Masuda; K Kato; M Hatanaka; S Harada
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

Review 7.  The use of baculoviruses as expression vectors.

Authors:  I M Kidd; V C Emery
Journal:  Appl Biochem Biotechnol       Date:  1993 Aug-Sep       Impact factor: 2.926

Review 8.  Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Authors:  Risto S Cvetkovic; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Identification and analysis of the gag-pol ribosomal frameshift site of feline immunodeficiency virus.

Authors:  S Morikawa; D H Bishop
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.